地榆升白片预防化疗引起骨髓抑制的临床观察

目的:观察地榆升白片对恶性肿瘤患者化疗引起的骨髓抑制的预防效果。方法:全组88例恶性肿瘤患者随机分为治疗组46例和对照组42例。治疗组在化疗同时服用地榆升白片,每次4片,每日3次,20 d为1个疗程。对照组化疗同时服用利血生和鯊肝醇,利血生片每次20 mg,鯊肝醇片每次100 mg,均每天3次,20 d为1个疗程。两组患者均完成2个周期化疗。结果:治疗组化疗后骨髓抑制发生率为37.0%,对照组为78.6%,两组比较有显著性差异(P<0.05),粒细胞集落刺激因子用量治疗组低于对照组,两组间有显著性差异(P<0.05),白细胞减少继发感染情况治疗组低于对照组。结论:地榆升白片能有效预防化疗引起的骨髓抑制。

Observation on Diyushengbai tablet to prevent myelosupression of patients treated by chemotherapy

Objective: TO evaluate the effect of the Diyushengbai tablet to prevent myelosuppression of patients with malignant tumor after chemotherapy.Methods:88 patients with malignant tumor were enrolled in our study and were randomized into the treatment group,which consisted of 46 cases using Diyushengbai tablets combined with chemotherapy,and the control group in which the patients were treated by leucogen tablets,batilol tablets combined with chemotherapy.The patients in the treatment group were advised to take orally 4 Diyushengbai tablets,three time per day,and those in the control group were given leucogen tablets,batilol tablets,20 mg and 100 mg respectively,both three time per day.All patients were treated with 2 cycles of regimen that continued 20 days.Results: The incidence of myelosuppression in the treatment group was significantly lower than that in the control group(37.0% vs 78.6%,P<0.05),and so did the means of used dose of recombinant human granulocyte colony stimulating factor(rhG-CSF)(81.5% vs 53.9%,P<0.05) and the side effects in the treatment group were less and milder than those in the control group.Conclusion: Diyushengbai tablet plays a significant role of enhancing chemotherapy,and alleviated the adverse effects of chemotherapy.